Vascular calcification in chronic kidney disease: New developments in drug therapy

Kidney International

Volumn 72, Issue 6, 2007, Pages 663-665

  Huybers, S ^a   Bindels, R J M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; VITAMIN D; VITAMIN D RECEPTOR;

BLOOD VESSEL CALCIFICATION; CALCIUM ABSORPTION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERTHYROIDISM; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 34548475293     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002477     Document Type: Note

References (13)

1. Cozzolino M, Brancaccio D, Gallieni M et al. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-436.
2. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-1059.
3. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867.
4. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299.
5. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14: S300-S304.
6. Mizobuchi M, Ogata H, Hatamura I et al. Upregulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant 2006; 21: 911-916.
7. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184.
8. Drissi H, Pouliot A, Koolloos C et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/ Cbfa1 gene promoter. Exp Cell Res 2002; 274: 323-333.
9. Virdi AS, Cook LJ, Oreffo RO et al. Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Cell Mol Biol (Noisy-le-grand) 1998; 44: 1237-1246.
10. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
11. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
12. Dobrez DG, Mathes A, Amdahl M et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004; 19: 1174-1181.
13. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.